Click on image to view larger version.

Figure 5 Effect of atorvastatin on Fas ligand (FasL) expression and solubilized Fas ligand (sFasL) released by human cultured endothelial cells (ECs). Endothelial cells were preincubated for 2 h with atorvastatin (Atv). (A) Western blot showing the effect of atorvastatin on FasL expression in ECs. (B) TNF-alpha decreased sFasL release by ECs at 6 h. Treatment with atorvastatin normalized circulating sFasL levels in a dose-dependent manner. *p < 0.05 vs. baseline; p < 0.05 vs. 25 ng/ml tumor necrosis factor (TNF)-alpha. (C) Treatment with atorvastatin (10 µmol/l) prevented the diminution of sFasL induced by TNF-alpha (*p < 0.05 vs. 25 ng/ml TNF-alpha).